# Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

> **NCT02236572** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 17 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02236572
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-29
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur.
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02236572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02236572, "Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02236572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*